Page last updated: 2024-11-06

dodecyltetraethylene glycol monoether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Dodecyltetraethylene glycol monoether (also known as C12E4) is a nonionic surfactant. It is synthesized through the reaction of dodecanol with ethylene oxide. C12E4 finds applications in various fields due to its properties as a wetting agent, emulsifier, and dispersant. It is commonly used in cosmetics, detergents, and industrial cleaning formulations. The amphiphilic nature of C12E4 enables it to effectively reduce surface tension, facilitating the dispersion of oil and water. Research on C12E4 focuses on understanding its interactions with different substrates, its environmental impact, and its potential applications in drug delivery systems. '
```

Cross-References

ID SourceID
PubMed CID78933
CHEMBL ID500128
CHEBI ID181087
SCHEMBL ID43045
MeSH IDM0150581

Synonyms (79)

Synonym
CHEBI:181087
2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethanol
c-12-e-4
ethanol, 2-(2-(2-(2-(dodecyloxy)ethoxy)ethoxy)ethoxy)-
dodecyltetraethylene glycol monoether
einecs 226-097-1
c12eo4
dodecyl-tetraethyleneoxide ether
nsc 190605
dodecyl tetra(oxyethylene) ether
tetraethylene glycol monododecyl ether
tetraethylene glycol dodecyl ether
nsc-190605
n-dodecyl tetraethylene glycol ether
5274-68-0
la 4
lauryl alcohol tri(oxyethylene) ethanol
tetra(oxydiethanol) monodecyl ether
tetraethylene glycol monolauryl ether
3,9,12-tetraoxatetracosan-1-ol
nsc190605
tetraoxyethylene glycol monododecyl ether
ethanol, 2-[2-[2-[2-(dodecyloxy)ethoxy]ethoxy]ethoxy]-
tetra(oxyethylene) dodecyl ether
laureth-4
NCGC00159385-02
NCGC00159385-03
brij(r) l4, average mn ~362
dodecyltetraglycol
tetraethylene glycol monododecyl ether, bioxtra, >=98.0% (gc)
3,6,9,12-tetraoxatetracosan-1-ol
T0769
lanycol-30
pegnol l-4
procol la-4
nikkol bl-4.2
jeecol la-4
unicol la-4
unihydol ls-4
brij-30
hetoxol la-4
brijl4-lq
peg-4 lauryl ether
brij l4
lauromacrogol 200
ethal la-4
akypo rox rlm 40
lipocol l-4
safol 23e4 ethoxylate
genapol la 040
rhodasurf l-4
CHEMBL500128
empilan kbe4
macrogol 2 lauryl ether
lumulse l-4
mulsifan cpa
marlowet bl
ethosperse la-4
FT-0627728
AKOS015902798
SCHEMBL43045
DTXSID3063752
tetraethylene glycol mono-n-dodecyl ether
WPMWEFXCIYCJSA-UHFFFAOYSA-N
mfcd00043063
tetraethyleneglycol monododecyl ether
tetraethylenen glycol mono-n-dodecyl ether
c12-alcohol-4-ethoxylate
c12-aeo-4
FT-0710803
Q63395633
T72570
A870917
AS-75638
CS-0152178
peg 4 lauryl ether
HY-W099536
3,6,9,12-tetraoxa-1-tetracosanol
SY076049
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
poly(ethylene glycol)A polymer composed of repeating ethyleneoxy units.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency36.25295.623417.292931.6228AID485281
Microtubule-associated protein tauHomo sapiens (human)Potency22.38720.180013.557439.8107AID1460
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency15.84890.00798.23321,122.0200AID2551
DNA polymerase kappa isoform 1Homo sapiens (human)Potency35.48130.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID555399Induction of toxin TSST-1 production in Staphylococcus aureus FRI-1169 at 10 mM after 32 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID555398Induction of toxin TSST-1 production in Staphylococcus aureus FRI-1169 at 2 mM after 32 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID555402Induction of toxin TSST-1 production in Staphylococcus aureus MN8 derivative 1 at 10 mM after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID362078Growth inhibition of human MOLT4 cells after 5 days by MTT assay2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Selective inhibitory effects of hybrid liposomes on the growth of HIV type 1-infected cells in vitro.
AID555400Induction of toxin TSST-1 production in Staphylococcus aureus FRI-1169 at 20 mM after 32 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID555396Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 10 mM after 28 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID362080Selectivity index, ratio of IC50 for HIV 3B infected cells to IC50 for human MOLT4 cells2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Selective inhibitory effects of hybrid liposomes on the growth of HIV type 1-infected cells in vitro.
AID555553Induction of toxin TSST-1 production in Staphylococcus aureus MN8 derivative 2 at 10 mM after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID362079Growth inhibition of HIV1 3B infected human MOLT4 cells after 5 days by MTT assay2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Selective inhibitory effects of hybrid liposomes on the growth of HIV type 1-infected cells in vitro.
AID555395Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 2 mM after 26 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID555401Induction of toxin TSST-1 production in Staphylococcus aureus FRI-1187 at 10 mM after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID555397Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 20 mM after 26 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.14)18.7374
1990's3 (21.43)18.2507
2000's6 (42.86)29.6817
2010's4 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.11 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]